Conference call for investors, analysts and the media, Monday, January 27[th] 2020, at 11 (CET).
Phone numbers for participants from:
The conference call will also be streamed on the corporate website www.oncopeptides.com and via the link below.
The presentation will be available at:
www.oncopeptides.com / Investor Relations / Presentations / Presentation webcast melflufen mechanism-of-action/ (https://oncopeptides.se/en/presentation-webcast-melflufens-mechanism-of-action/)
For more information, please contact:
E-mail: rein.piir@oncopeptides.com
Cell phone: +46 70 853 72 92
This information was submitted for publication at 18.30 CET
About melflufen
Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular alkylator concentration. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.
About
https://news.cision.com/oncopeptides-ab/r/oncopeptides-will-host-a-webcast-on-monday--january-27-th--at-11-00--cet-,c3016794
https://mb.cision.com/Main/15404/3016794/1179485.pdf
(c) 2020 Cision. All rights reserved., source